Example: Heart Attack

Clinical Trials on Hematologic Neoplasms

Total 1467 results

NCT04557098

Not yet recruiting

A Study of Teclistamab, in Participants With Relapsed or Refractory Multiple Myeloma

Conditions: Hematological Malignancies
NCT04552288

Recruiting

Study of Benralizumab in People With Skin Side Effects Caused by Cancer Therapies

Conditions: Solid Tumor; Solid Carcinoma; Solid Tumor, Adult; Hematologic Malignancy
NCT04551053

Not yet recruiting

To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib

Conditions: Myelofibrosis; Primary Myelofibrosis; Post Essential Thrombocythemia Myelofibrosis; Post Polycythemia Vera Myelofibrosis
NCT04551066

Not yet recruiting

To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis

Conditions: Myelofibrosis; Primary Myelofibrosis; Post Essential Thrombocythemia Myelofibrosis; Post Polycythemia Vera Myelofibrosis
NCT04546945

Active, not recruiting

Aberrant Expression of CD56 in Patients With Hematologic Malignancies.

Conditions: Hematologic Malignancies
NCT04547049

Recruiting

A Study Comparing Haploidentical Hematopoietic Stem Cell Transplantations (HSCTs) From Young Non-first-degree and Older First-degree Donors in Hematological Malignancies

Conditions: Leukemia
NCT04547335

Recruiting

The Influence of CYP2C19 Polymorphisms on the Safety and Efficacy of Voriconazole

Conditions: Adverse Drug Reactions
NCT04545333

Not yet recruiting

The clonoSEQ® Watch Registry

Conditions: Acute Lymphoblastic Leukemia, Adult B-Cell; Chronic Lymphocytic Leukemia; Multiple Myeloma; Non-hodgkin Lymphoma
NCT04543305

Recruiting

A Study of PRT1419 in Patients With Relapsed/Refractory Hematologic Malignancies

Conditions: Multiple Myeloma; Acute Myeloid Leukemia; Non Hodgkin Lymphoma; Myelodysplastic Syndromes
NCT04538599

Recruiting

RD13-01 for Patients With r/r CD7+ T/NK Cell Hematologic Malignancies

Conditions: Hematologic Malignancies
NCT04537715

Recruiting

A Two-part Study to Characterize Drug-Drug Interaction Effects on Steady-State Pharmacokinetics of Oral Tazemetostat

Conditions: All Malignancies; Advanced Malignancies; Hematologic Malignancy; Solid Tumor; Follicular Lymphoma (FL); Non-Hodgkin Lymphoma (NHL); Diffuse Large B-Cell Lymphoma (DLBCL); Epithelioid Sarcoma (ES); Synovial Sarcoma; Renal Medullary Carcinoma; Mesothelioma; Rhabdoid Tumor
NCT04532203

Recruiting

A Study of CAR-T Cells Therapy for Patients With Relapsed and/or Refractory Central Nervous System Hematological Malignancies

Conditions: Acute Lymphoblastic Leukemia; Non-Hodgkin's Lymphoma
NCT04532281

Recruiting

A Study of Murine CD19 CAR-T Therapy for Patients With Relapsed or Refractory CD19+ B-cell Hematological Malignancies

Conditions: Acute Lymphoblastic Leukemia; Non-Hodgkin Lymphoma of Soft Tissue
NCT04517851

Not yet recruiting

Elotuzumab for the Treatment of JAK2-Mutated Myelofibrosis

Conditions: Myelofibrosis Transformation in Essential Thrombocythemia; Polycythemia Vera, Post-Polycythemic Myelofibrosis Phase; Primary Myelofibrosis
NCT04509765

Not yet recruiting

A Phase II Single-arm Study of Total Body Irradiation With Linac Based VMAT and IGRT

Conditions: Hematologic Malignancy
NCT04504708

Not yet recruiting

Dose-Escalation and Dose-Expansion Study of ZX-101A in Patients With Relapsed/Resistant or Refractory Advanced Hematologic Malignancies

Conditions: Non-hodgkin Lymphoma; Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma
NCT04500587

Not yet recruiting

Phase 1 Study of ZN-d5 as a Single Agent

Conditions: Acute Myeloid Leukemia; Non Hodgkin Lymphoma
NCT04497701

Not yet recruiting

Evaluate the Efficacy and Safety of the Prophylactic Use of PEG-rhG-CSF in Children With Hematological Malignancies

Conditions: Lymphoma; Leukemia
NCT04496375

Not yet recruiting

An Evaluation of Patients Access to Their Electronic Medical Records Via the IPC Connect Application

Conditions: Solid Tumor; Hematologic Malignancy
NCT04488354

Not yet recruiting

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

Conditions: Relapsed/Refractory B-cell Lymphomas; Diffuse Large B-Cell Lymphoma (DLBCL); Follicular Lymphoma (FL); Chronic Lymphocytic Leukemia (CLL); Marginal Zone Lymphoma (MZL); Mantle Cell Lymphoma (MCL); Small Lymphocytic Lymphoma (SLL); Primary Mediastinal Large B Cell Lymphoma; Transformed Follicular Lymphoma
NCT04485260

Not yet recruiting

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib

Conditions: Myelofibrosis
NCT04478916

Recruiting

Impact of the Comprehensive Geriatric Assessment on the Quality of Life OF Elderly Patients

Conditions: Hematologic Malignancies; Solid Tumor; Elderly Patients
NCT04477681

Recruiting

Securing Access to Innovative Molecules in Oncology and Hematology for Children, Adolescents and Young Adults

Conditions: Pediatric Cancer
NCT04478123

Recruiting

Using Romiplostim to Treat Low Platelet Counts Following Chemotherapy and Autologous Hematopoietic Cell Transplantation in People With Blood Cancer

Conditions: Multiple Myeloma; Hodgkin Lymphoma; Non-Hodgkin Lymphoma; HDT-AHCT
NCT04473937

Not yet recruiting

Radiation Post-CAR T in Refractory Lymphoma

Conditions: Hematologic Malignancy; Refractory Lymphoma
NCT04471961

Recruiting

Analyse of Tumour and Constitutional DNA for the Study of the Determinism in Child Neoplasia

Conditions: Pediatric Tumor; Familial Cancer; Solid Tumor, Childhood; Hematological Tumor
NCT04470947

Recruiting

Comprehensive Genomic Profiling and Next Generation Functional Drug Screening for Patients With Aggressive Haematological Malignancies

Conditions: Advanced Lymphoma; Refractory Lymphoma; Refractory Leukemia; Refractory Acute Myeloid Leukemia; Refractory T-Cell Lymphoma
NCT04466059

Not yet recruiting

Better Leukemia Diagnostics Through AI (BELUGA)

Conditions: Hematologic Malignancy; Leukemia; Minimal Residual Disease; Lymphoma; Blood Cancer
NCT04464889

Recruiting

HA-1H TCR T Cell for Relapsed/Persistent Hematologic Malignancies After Allogeneic Stem Cell Transplantation

Conditions: Acute Myeloid Leukemia; Acute Lymphoid Leukemia; Myelodysplastic Syndromes; Myeloproliferative Disorders; Chronic Myeloid Leukemia; Myelofibrosis; Multiple Myeloma; Malignant Lymphoma
NCT04455841

Not yet recruiting

INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders

Conditions: Anemia; Post-essential Thrombocythemia Myelofibrosis; Post-polycythemia Vera Myelofibrosis
NCT04456023

Not yet recruiting

Study of Tisagenlecleucel in Chinese Adult Patients With Relapsed or Refractory Diffuse Large B-cell Non-Hodgkin Lymphoma (DLBCL)

Conditions: Diffuse Large B-Cell Lymphoma (DLBCL)
NCT04454723

Not yet recruiting

Impact of Palliative Transfusions on Quality of Life in Patients With Blood Cancers on Hospice

Conditions: Hematologic Malignancy
NCT04450069

Recruiting

CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies

Conditions: Relapsed/Refractory B-cell Lymphomas; Diffuse Large B Cell Lymphoma (DLBCL); Follicular Lymphoma (FL); Chronic Lymphocytic Leukemia (CLL); Marginal Zone Lymphoma (MZL); Mantle Cell Lymphoma; Small Lymphocytic Lymphoma (SLL); Primary Mediastinal Large B Cell Lymphoma; Transformed Follicular Lymphoma
NCT04446650

Not yet recruiting

A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Conditions: Primary Myelofibrosis
NCT04448184

Not yet recruiting

Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH Trial)

Conditions: Hematologic Neoplasms
NCT04433871

Recruiting

COVID-19 in Pediatric Oncology and Hematology Centers in France

Conditions: Covid-19; Cancer
NCT04425642

Recruiting

Effects of Parenteral Nutrition in HSCT

Conditions: Hematologic Malignancy
NCT04425655

Not yet recruiting

Fludarabine in Combination With Daunorubicin and Cytarabine Liposome in Newly-diagnosed Acute Myeloid Leukemia.

Conditions: Acute Myeloid Leukemia, Adult; AML; AML, Adult
NCT04428918

Withdrawn

Biospecimen Procurement for Immunological Landscape Studies Following Hematopoietic Cell Transplantation

Conditions: Hematopoietic Stem Cell Transplantation; Cell Transplantation; Hematologic Malignancies
NCT04419623

Recruiting

A Study of TL-895 With Standard Available Treatment Versus Standard Available Treatment for the Treatment of COVID-19 in Patients With Cancer

Conditions: COVID-19; Sars-CoV2; Cancer; Solid Tumor; Carcinoma; Blood Cancer
NCT04412135

Not yet recruiting

The Point of View of Hematological Cancer Patients and Their Loved Ones Regarding Spirituality

Conditions: Hematologic Cancer
NCT04412577

Not yet recruiting

A Study of TQB3473 Tablets in Subjects With Relapsed or Refractory Hematological Malignancies

Conditions: Relapsed/Refractory Hematological Malignancies
NCT04406285

Not yet recruiting

Effects of Periodized and Autoregulated Resistance Training in Haematological Cancer Patients During the Treatent.

Conditions: Fatigue; Leukemia; Lymphoma; Physical Disability
NCT04397705

Not yet recruiting

Remote Monitoring of Cancer Patients With Suspected Covid-19

Conditions: COVID; Oncology; Haematological Malignancy
NCT04395222

Recruiting

Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation

Conditions: Hematologic Malignancy; Bone Marrow Transplant
NCT04393363

Recruiting

Early Detection of Neuropathy and Cognitive Impairment Following Treatment for Haematological Malignancies

Conditions: Chemotherapy-induced Peripheral Neuropathy
NCT04392128

Withdrawn

Study Evaluating the Efficacy of Hydroxychloroquine and Azithromycine in Patients With COVID-19 and Hematological Malignancies (HYACINTHE)

Conditions: COVID19; Hematologic Malignancy
NCT04389541

Recruiting

Clinical Research Platform on Decision Making and Clinical Impact of Biomarker-Driven Precision Oncology

Conditions: Advanced Hematologic Malignancy or Solid Tumor
NCT04390542

Not yet recruiting

Intervention for Caregivers of Patients Undergoing HSCT or CAR T-cell Therapy

Conditions: Blood Cancer
NCT04372524

Not yet recruiting

Biomarker Verification in Pediatric Chronic GvHD: ABLE 2.0 / PBMTC 1901 Study

Conditions: Chronic Graft-versus-Host-Disease; Leukemia; Allogeneic Hematopoietic Stem Cell Transplantation; Blood Cancer; Non-Malignant Hematologic and Lymphocytic Disorder

COOKIE SETTINGS

Clinical Trials on Hematologic Neoplasms